Tumore al seno - superare la paura e favorire la guarigione
Dr. Lecia Sequist: Can We Bring The Advances in Targeted Therapy to Squamous NSCLC and Broader NSCLC Populations?
Dr. Sarah Goldberg: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?
Dr. Karen Kelly: What Molecular Markers Do You Routinely Send for in Your Patients with Advanced Non-Small Cell Lung Cancer?
Drs. Ross Camidge and Corey Langer: Who Do You Recommend Repeat Biopsy for if There Isn’t Enough Tissue for Molecular Testing?
Drs. Ross Camidge and Corey Langer: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Karen Kelly: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
Dr. Karen Reckamp on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Drs. Ross Camidge and Corey Langer on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Dr. Karen Reckamp: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Ravi Salgia: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Sarah Goldberg on "Which molecular marker tests do you seek?"
Drs. Ross Camidge and Corey Langer on "Which patients do you send molecular marker testing for?"
Dr. Bob Doebele: Will We Be Able to Use Molecular Markers and Apply Targeted Therapies to Broader Lung Cancer Subtypes in the Near Future?
Dr. Greg Riely: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
Dr. Karen Reckamp: Recommending a Repeat Biopsy, at Initial Diagnosis or with Acquired Resistance to a Targeted Therapy
Dr. David Spigel: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?
Dr. Rosalyn Juergens: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Greg Riely: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Heather Wakelee on "Which molecular marker tests do you seek?"
Dr. Ravi Salgia on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Dr. Rosalyn Juergens: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
Dr. Sarah Goldberg: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
Dr. Phil Bonomi, Rush University: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Heather Wakelee: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Phil Bonomi: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
Dr. Sarah Goldberg: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Sarah Goldberg on "Which patients do you send molecular marker testing for?"
Dr. David Spigel: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. David Spigel on "Which molecular marker tests do you seek?"
Dr. Greg Riely on "Which patients do you send molecular marker testing for, and what tests do you seek?"
Dr. Rosalyn Juergens: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?
ALK Positive Lung Cancer Forum 2014: ALK Rearrangements in Lung Cancer
Bronchioloalveolar Carcinoma (BAC): What is It?
Myths and Misconceptions About Bronchioloalveolar Carcinoma (BAC)
Optimal Systemic Therapy for Bronchioloalveolar Carcinoma (BAC)
What is EGFR and the EGFR Mutation?
Are There Distinctions Among Currently Available Oral EGFR Inhibitors for EGFR Mutation-Positive NSCLC?
First Line Treatment of EGFR Mutation-Positive NSCLC
Surgery Options for Smaller, Slow-Growing Lung Cancers
Differences Among Specific EGFR Mutations
Should EGFR TKI Therapy be Continued Beyond Progression?
Patterns of Acquired Resistance to EGFR TKIs in EGFR Mutation-Positive NSCLC
Different Lung Cancer Subtypes - Histology
Histology-Specific Regimens - Adenocarcinoma
ALK Rearrangements: What Are They, and Who Has Them?
Case Based Panel Discussion 2.1 Patient with Good Performance Status, Lung Adenocarcinoma, Metastatic Disease Adrenal Lesion
TWiM #104: Feed me polyamines, biofilm
Scopri di più
Cerca
